Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Myriad Genetics Inc | MYGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.98 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 13.82 - 24.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 17.98 | USD |
Myriad Genetics (MYGN) Options Flow Summary
Myriad Genetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.62B | 89.87M | - | 753.2M | -263.3M | -2.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Myriad Genetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MYGN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 18.47 | 19.00 | 17.92 | 18.42 | 508,859 | -0.49 | -2.65% |
1 Month | 21.35 | 21.48 | 17.92 | 19.54 | 544,393 | -3.37 | -15.78% |
3 Months | 21.50 | 23.75 | 17.92 | 21.37 | 627,676 | -3.52 | -16.37% |
6 Months | 14.80 | 23.75 | 13.82 | 19.90 | 668,998 | 3.18 | 21.49% |
1 Year | 21.32 | 24.21 | 13.82 | 19.67 | 598,266 | -3.34 | -15.67% |
3 Years | 30.37 | 36.9547 | 13.82 | 22.66 | 577,645 | -12.39 | -40.80% |
5 Years | 31.60 | 48.40 | 9.24 | 22.43 | 733,318 | -13.62 | -43.10% |
Myriad Genetics Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |